Successful rights offer is oversubscribed

Ma te huruhuru te manu ka rere, tena koutou nga kaipupuri hea i whakapono mai ki te tono no tata tonu nei. He tohu tenei, he pakari te haere o te kamupene, he totika hoki nga whakahaere. Mei kore ko koutou, ka kore hoki tenei manu e rere.

Because of its feathers, the bird flies. Best wishes to the shareholders who believed in us by supporting our recent request for support. This is a sign that our company is strong, and that our operations are solid. If it weren’t for you this bird would not fly.

Rua Bioscience Limited announces the successful completion of its 1 for 3 renounceable rights offer at an issue price of $0.025 per new share. The rights offer sought to raise $2.034 million.

The rights issue which closed on Friday 12 December 2025, was oversubscribed with applications received of $2.316 mill. This is $282k or 14% more than the amount requested under the offer.

The Board has resolved to accept oversubscriptions in excess of the rights offer through a placement to an existing eligible investor of approximately $280,000, at the same issue price of $0.025 per share.

The allotment and issue of new shares will occur on Thursday 18 December 2025. Holding Statements will be dispatched to shareholders on Monday 22 December 2025

Rua Bioscience Chair, Anna Stove commented, “The strong level of shareholder support is a clear endorsement of our strategy and the progress being made by the Rua team. On behalf of the Board and the Rua team, I would like to thank our shareholders for their continued support.”

Rua Bioscience remains committed to its export-led growth strategy, leveraging its international partnerships and it’s expertise in unique genetic development to deliver high-value medicinal cannabis products to patients.